Swapnil Potdar
Overview
Explore the profile of Swapnil Potdar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
389
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Adnan Awad S, Dufva O, Klievink J, Karjalainen E, Ianevski A, Pietarinen P, et al.
Cell Rep Med
. 2024 Apr;
5(5):101521.
PMID: 38653245
BCR::ABL1-independent pathways contribute to primary resistance to tyrosine kinase inhibitor (TKI) treatment in chronic myeloid leukemia (CML) and play a role in leukemic stem cell persistence. Here, we perform ex ...
2.
Mendiola M, Saarela J, Escudero F, Heredia-Soto V, Potdar S, Rodriguez-Marrero S, et al.
Biomed Pharmacother
. 2024 Mar;
173:116397.
PMID: 38479181
Angiosarcoma is a rare soft tissue sarcoma originating from endothelial cells. Given that current treatments for advanced disease have shown limited efficacy, alternative therapies need to be identified. In rare...
3.
Bogacheva M, Kuivanen S, Potdar S, Hassinen A, Huuskonen S, Pohner I, et al.
Antiviral Res
. 2024 Jan;
223:105813.
PMID: 38272320
The coronavirus disease 2019 (COVID-19) pandemic has heavily challenged the global healthcare system. Despite the vaccination programs, the new virus variants are circulating. Further research is required for understanding of...
4.
Chen Y, He L, Ianevski A, Ayuda-Duran P, Potdar S, Saarela J, et al.
Nat Protoc
. 2023 Nov;
19(1):60-82.
PMID: 37996540
Most patients with advanced malignancies are treated with severely toxic, first-line chemotherapies. Personalized treatment strategies have led to improved patient outcomes and could replace one-size-fits-all therapies, yet they need to...
5.
Rizzo A, Maresca C, DAngelo C, Porru M, Di Vito S, Salvati E, et al.
Aging Cell
. 2023 Oct;
22(11):e13944.
PMID: 37858982
Drug repositioning strategy represents a valid tool to accelerate the pharmacological development through the identification of new applications for already existing compounds. In this view, we aimed at discovering molecules...
6.
Pietiainen V, Polso M, Migh E, Guckelsberger C, Harmati M, Diosdi A, et al.
Cell Rep Methods
. 2023 Sep;
3(8):100565.
PMID: 37671026
We present a miniaturized immunofluorescence assay (mini-IFA) for measuring antibody response in patient blood samples. The method utilizes machine learning-guided image analysis and enables simultaneous measurement of immunoglobulin M (IgM),...
7.
Potdar S, Ianevski F, Ianevski A, Tanoli Z, Wennerberg K, Seashore-Ludlow B, et al.
Nucleic Acids Res
. 2023 May;
51(W1):W57-W61.
PMID: 37178002
Functional precision medicine (fPM) offers an exciting, simplified approach to finding the right applications for existing molecules and enhancing therapeutic potential. Integrative and robust tools ensuring high accuracy and reliability...
8.
Feodoroff M, Mikkonen P, Turunen L, Hassinen A, Paasonen L, Paavolainen L, et al.
SLAS Discov
. 2023 Mar;
28(4):138-148.
PMID: 36934951
Central to the success of functional precision medicine of solid tumors is to perform drug testing of patient-derived cancer cells (PDCs) in tumor-mimicking ex vivo conditions. While high throughput (HT)...
9.
Angori S, Banaei-Esfahani A, Muhlbauer K, Bolck H, Kahraman A, Karakulak T, et al.
Eur Urol Focus
. 2023 Mar;
9(5):751-759.
PMID: 36933996
Background: Immune checkpoint inhibitors and antiangiogenic agents are used for first-line treatment of advanced papillary renal cell carcinoma (pRCC) but pRCC response rates to these therapies are low. Objective: To...
10.
Wang Z, Macakova M, Bugai A, Kuznetsov S, Hassinen A, Lenasi T, et al.
Nucleic Acids Res
. 2023 Feb;
51(4):1687-1706.
PMID: 36727434
Positive transcription elongation factor b (P-TEFb) is the crucial player in RNA polymerase II (Pol II) pause release that has emerged as a promising target in cancer. Because single-agent therapy...